{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:49:22Z","timestamp":1793148562722,"version":"4.5.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:00:00Z","timestamp":1728604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:00:00Z","timestamp":1728604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81871071"],"award-info":[{"award-number":["81871071"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82288101"],"award-info":[{"award-number":["82288101"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7222109"],"award-info":[{"award-number":["7222109"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Clinical Research Centre for Mental Disorder (Peking University Sixth Hospital), the key research project of independent exploration in 2021"},{"name":"National Programs for Brain Science and Brain-like Intelligence Technology of China"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1038\/s41380-024-02782-4","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T12:01:55Z","timestamp":1728648115000},"page":"1758-1769","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Incidence and risk factors of antidepressant withdrawal symptoms: a meta-analysis and systematic review"],"prefix":"10.1038","volume":"30","author":[{"given":"Mi-Mi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Bo","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9522-918X","authenticated-orcid":false,"given":"Na","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1318-2029","authenticated-orcid":false,"given":"Mark Abie","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Zhu","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Li","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0081-6048","authenticated-orcid":false,"given":"Peng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6567-8160","authenticated-orcid":false,"given":"Jie","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1881-0939","authenticated-orcid":false,"given":"Yan-Ping","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0742-9072","authenticated-orcid":false,"given":"Lin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0781-0300","authenticated-orcid":false,"given":"Su-Xia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,11]]},"reference":[{"key":"2782_CR1","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/01.yic.0000194377.88330.1d","volume":"21","author":"DS Baldwin","year":"2006","unstructured":"Baldwin DS, Cooper JA, Huusom AK, Hindmarch I. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. Int Clin Psychopharmacol. 2006;21:159\u201369.","journal-title":"Int Clin Psychopharmacol"},{"key":"2782_CR2","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1192\/bjp.167.3.374","volume":"167","author":"S Oehrberg","year":"1995","unstructured":"Oehrberg S, Christiansen PE, Behnke K, Borup AL, Severin B, Soegaard J, et al. Paroxetine in the treatment of panic disorder a randomised, double-blind, placebo-controlled study. Br J Psychiatry. 1995;167:374\u201379.","journal-title":"Br J Psychiatry"},{"key":"2782_CR3","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1192\/bjp.bp.105.012799","volume":"189","author":"DS Baldwin","year":"2006","unstructured":"Baldwin DS, Huusom AK, Maehlum E. Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study. Br J Psychiatry. 2006;189:264\u201372.","journal-title":"Br J Psychiatry"},{"key":"2782_CR4","first-page":"28","volume":"52","author":"DJ Kupfer","year":"1991","unstructured":"Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry. 1991;52:28\u201334.","journal-title":"J Clin Psychiatry"},{"key":"2782_CR5","unstructured":"Pratt LA, Brody DJ, Gu QP. NCHS Data Brief No. 283 (ed CDC) (Centers for Disease Control and Prevention, https:\/\/www.cdc.gov\/nchs\/products\/databriefs\/db283.htm, 2017)."},{"key":"2782_CR6","doi-asserted-by":"publisher","first-page":"e773","DOI":"10.3399\/bjgp12X658304","volume":"62","author":"CF Johnson","year":"2012","unstructured":"Johnson CF, Macdonald HJ, Atkinson P, Buchanan AI, Downes N, Dougall N. Reviewing long-term antidepressants can reduce drug burden: a prospective observational cohort study. Br J Gen Pract. 2012;62:e773\u20139.","journal-title":"Br J Gen Pract"},{"key":"2782_CR7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/070674375900400111","volume":"4","author":"AM Mann","year":"1959","unstructured":"Mann AM, MacPherson AS. Clinical experience with imipramine (G 22355) in the treatment of depression. Can Psychiatry Assoc J. 1959;4:38\u201347.","journal-title":"Can Psychiatry Assoc J"},{"key":"2782_CR8","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1192\/apt.bp.105.001966","volume":"13","author":"PM Haddad","year":"2007","unstructured":"Haddad PM, Anderson IM. Recognising and managing antidepressant discontinuation symptoms. Adv Psychiatry Treat. 2007;13:447\u201357.","journal-title":"Adv Psychiatry Treat"},{"key":"2782_CR9","first-page":"9","volume":"48","author":"RH Howland","year":"2010","unstructured":"Howland RH. Potential adverse effects of discontinuing psychotropic drugs: part 2: antidepressant drugs. J Psychosoc Nurs Ment Health Serv. 2010;48:9\u201312.","journal-title":"J Psychosoc Nurs Ment Health Serv"},{"key":"2782_CR10","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1177\/026988119801200311","volume":"12","author":"P Haddad","year":"1998","unstructured":"Haddad P. The SSRI discontinuation syndrome. J Psychopharmacol. 1998;12:305\u201313.","journal-title":"J Psychopharmacol"},{"key":"2782_CR11","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3390\/ph14050451","volume":"14","author":"M Siwek","year":"2021","unstructured":"Siwek M, Chrobak AA, Gorostowicz A, Krupa AJ, Dudek D. Withdrawal symptoms following discontinuation of vortioxetine\u2014retrospective chart review. Pharmaceuticals. 2021;14:451.","journal-title":"Pharmaceuticals"},{"key":"2782_CR12","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/00004850-200015060-00001","volume":"15","author":"I Hindmarch","year":"2000","unstructured":"Hindmarch I, Kimber S, Cockle SM. Abrupt and brief discontinuation of antidepressant treatment: effects on cognitive function and psychomotor performance. Int Clin Psychopharmacol. 2000;15:305\u201318.","journal-title":"Int Clin Psychopharmacol"},{"key":"2782_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.addbeh.2018.08.027","volume":"97","author":"J Davies","year":"2019","unstructured":"Davies J, Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: are guidelines evidence-based? Addict Behav. 2019;97:111\u201321.","journal-title":"Addict Behav"},{"key":"2782_CR14","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1176\/appi.ajp.2018.18060692","volume":"175","author":"MK Jha","year":"2018","unstructured":"Jha MK, Rush AJ, Trivedi MH. When discontinuing SSRI antidepressants is a challenge: management tips. Am J Psychiatry. 2018;175:1176\u201384.","journal-title":"Am J Psychiatry"},{"key":"2782_CR15","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/S2215-0366(19)30032-X","volume":"6","author":"MA Horowitz","year":"2019","unstructured":"Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry. 2019;6:538\u201346.","journal-title":"Lancet Psychiatry"},{"key":"2782_CR16","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group* P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264\u201369.","journal-title":"Ann Intern Med"},{"key":"2782_CR17","first-page":"14","volume":"67","author":"M Fava","year":"2006","unstructured":"Fava M. Prospective studies of adverse events related to antidepressant discontinuation. J Clin Psychiatry. 2006;67:14\u201321.","journal-title":"J Clin Psychiatry"},{"key":"2782_CR18","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1176\/ajp.139.3.325","volume":"139","author":"D Bialos","year":"1982","unstructured":"Bialos D, Giller E, Jatlow P, Docherty J, Harkness L. Recurrence of depression after discontinuation of long-term amitriptyline treatment. Am J Psychiatry. 1982;139:325\u20139.","journal-title":"Am J Psychiatry"},{"key":"2782_CR19","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1097\/00004714-198708000-00008","volume":"7","author":"B Geller","year":"1987","unstructured":"Geller B, Cooper TB, Carr LG, Warham JE, Rodriguez A. Prospective study of scheduled withdrawal from nortriptyline in children and adolescents. J Clin Psychopharmacol. 1987;7:252\u20134.","journal-title":"J Clin Psychopharmacol"},{"key":"2782_CR20","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/(SICI)1099-1077(199607)11:4<337::AID-HUP779>3.0.CO;2-2","volume":"11","author":"S Bhuamik","year":"1996","unstructured":"Bhuamik S, Wildgust HJ. Treatment outcomes including withdrawal phenomena with fluoxetine and paroxetine in patients with learning disabilities suffering from affective disorders. Hum Psychopharmacol Clin Exp. 1996;11:337\u201338.","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"2782_CR21","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1176\/ajp.154.12.1760","volume":"154","author":"M Fava","year":"1997","unstructured":"Fava M, Mulroy R, Alpert J, Nierenberg AA, Rosenbaum JF. Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Am J Psychiatry. 1997;154:1760\u20132.","journal-title":"Am J Psychiatry"},{"key":"2782_CR22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0006-3223(98)00126-7","volume":"44","author":"JF Rosenbaum","year":"1998","unstructured":"Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998;44:77\u201387.","journal-title":"Biol Psychiatry"},{"key":"2782_CR23","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/00004714-199806000-00003","volume":"18","author":"J Zajecka","year":"1998","unstructured":"Zajecka J, Fawcett J, Amsterdam J, Quitkin F, Reimherr F, Rosenbaum J, et al. Safety of abrupt discontinuation of fluoxetine: a randomized, placebo-controlled study. J Clin Psychopharmac. 1998;18:193\u201397.","journal-title":"J Clin Psychopharmac"},{"key":"2782_CR24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2165\/00023210-200216040-00006","volume":"16","author":"F Bogetto","year":"2002","unstructured":"Bogetto F, Bellino S, Revello RB, Patria L. Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors. CNS Drugs. 2002;16:273\u201383.","journal-title":"CNS Drugs"},{"key":"2782_CR25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/00004850-200209000-00002","volume":"17","author":"R Judge","year":"2002","unstructured":"Judge R, Parry MG, Quail D, Jacobson JG. Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment. Int Clin Psychopharmacol. 2002;17:217\u201325.","journal-title":"Int Clin Psychopharmacol"},{"key":"2782_CR26","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/hup.644","volume":"19","author":"P Vandel","year":"2004","unstructured":"Vandel P, Sechter D, Weiller E, Pezous N, Cabanac F, Tournoux A, et al. Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine. Hum Psychopharmacol. 2004;19:585\u20136.","journal-title":"Hum Psychopharmacol"},{"key":"2782_CR27","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.4088\/JCP.v66n1009","volume":"66","author":"SA Montgomery","year":"2005","unstructured":"Montgomery SA, Nil R, D\u00fcrr-Pal N, Loft H, Boulenger JP. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry. 2005;66:1270\u20138.","journal-title":"J Clin Psychiatry"},{"key":"2782_CR28","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00228-005-0921-x","volume":"61","author":"EC van Geffen","year":"2005","unstructured":"van Geffen EC, Hugtenburg JG, Heerdink ER, van Hulten RP, Egberts AC. Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation. Eur J Clin Pharmacol. 2005;61:303\u20137.","journal-title":"Eur J Clin Pharmacol"},{"key":"2782_CR29","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2165\/00023210-200620080-00005","volume":"20","author":"A Himei","year":"2006","unstructured":"Himei A, Okamura T. Discontinuation syndrome associated with paroxetine in depressed patients. CNS Drugs. 2006;20:665\u201372.","journal-title":"CNS Drugs"},{"key":"2782_CR30","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1017\/S1461145706007462","volume":"10","author":"GA Fava","year":"2007","unstructured":"Fava GA, Bernardi M, Tomba E, Rafanelli C. Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia. Int J Neuropsychopharmacol. 2007;10:835\u20138.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2782_CR31","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2147\/nedt.2007.3.1.181","volume":"3","author":"F Okada","year":"2007","unstructured":"Okada F. Why does milnacipran produce so few discontinuation syndromes following abrupt withdrawal? Neuropsychiatr Dis Treat. 2007;3:181\u20132.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2782_CR32","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1177\/0269881107081550","volume":"22","author":"A Tint","year":"2008","unstructured":"Tint A, Haddad PM, Anderson IM. The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study. J Psychopharmacol. 2008;22:330\u20132.","journal-title":"J Psychopharmacol"},{"key":"2782_CR33","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1097\/YIC.0b013e32832fbb5a","volume":"24","author":"SA Montgomery","year":"2009","unstructured":"Montgomery SA, Fava M, Padmanabhan SK, Guico-Pabia CJ, Tourian KA. Discontinuation symptoms and taper\/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder. Int Clin Psychopharmacol. 2009;24:296\u2013305.","journal-title":"Int Clin Psychopharmacol"},{"key":"2782_CR34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/JCP.0b013e3181c8ae80","volume":"30","author":"Y Murata","year":"2010","unstructured":"Murata Y, Kobayashi D, Imuta N, Haraguchi K, Ieiri I, Nishimura R, et al. Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome. J Clin Psychopharmacol. 2010;30:11\u201317.","journal-title":"J Clin Psychopharmacol"},{"key":"2782_CR35","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/JCP.0000000000000100","volume":"34","author":"A Khan","year":"2014","unstructured":"Khan A, Musgnung J, Ramey T, Messig M, Buckley G, Ninan PT. Abrupt discontinuation compared with a 1-week taper regimen in depressed outpatients treated for 24 weeks with desvenlafaxine 50 mg\/d. J Clin Psychopharmacol. 2014;34:365\u20138.","journal-title":"J Clin Psychopharmacol"},{"key":"2782_CR36","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/WNF.0000000000000139","volume":"39","author":"N Yasui-Furukori","year":"2016","unstructured":"Yasui-Furukori N, Hashimoto K, Tsuchimine S, Tomita T, Sugawara N, Ishioka M, et al. Characteristics of escitalopram discontinuation syndrome: a preliminary study. Clin Neuropharmacol. 2016;39:125\u20137.","journal-title":"Clin Neuropharmacol"},{"key":"2782_CR37","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1002\/phar.1992","volume":"37","author":"TB Bainum","year":"2017","unstructured":"Bainum TB, Fike DS, Mechelay D, Haase KK. Effect of abrupt discontinuation of antidepressants in critically ill hospitalized adults. Pharmacother: J Hum Pharmacol Drug Ther. 2017;37:1231\u201340.","journal-title":"Pharmacother: J Hum Pharmacol Drug Ther"},{"key":"2782_CR38","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1111\/inm.12488","volume":"27","author":"J Read","year":"2018","unstructured":"Read J, Cartwright C, Gibson K. How many of 1829 antidepressant users report withdrawal effects or addiction? Int J Mental Health Nurs. 2018;27:1805\u201315.","journal-title":"Int J Mental Health Nurs"},{"key":"2782_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2019.106157","volume":"102","author":"J Read","year":"2020","unstructured":"Read J. How common and severe are six withdrawal effects from, and addiction to, antidepressants? The experiences of a large international sample of patients. Addict Behav. 2020;102:106157.","journal-title":"Addict Behav"},{"key":"2782_CR40","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1007\/s10597-019-00535-0","volume":"56","author":"J Read","year":"2020","unstructured":"Read J, Grigoriu M, Gee A, Diggle J, Butler H. The positive and negative experiences of 342 antidepressant users. Community Ment Health J. 2020;56:744\u201352.","journal-title":"Community Ment Health J"},{"key":"2782_CR41","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1176\/ajp.150.1.165a","volume":"150","author":"A Ceccherini-Nelli","year":"1993","unstructured":"Ceccherini-Nelli A, Bardellini L, Cur A, Guazzelli M, Maggini C, Dilsaver SC. Antidepressant withdrawal: prospective findings. Am J Psychiatry. 1993;150:165.","journal-title":"Am J Psychiatry"},{"key":"2782_CR42","first-page":"146","volume":"54","author":"DW Black","year":"1993","unstructured":"Black DW, Wesner R, Gabel J. The abrupt discontinuation of fluvoxamine in patients with panic disorder. J Clin Psychiatry. 1993;54:146\u20139.","journal-title":"J Clin Psychiatry"},{"key":"2782_CR43","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/00004850-200015060-00003","volume":"15","author":"JS Markowitz","year":"2000","unstructured":"Markowitz JS, DeVane CL, Liston HL, Montgomery SA. An assessment of selective serotonin reuptake inhibitor discontinuation symptoms with citalopram. Int Clin Psychopharmacol. 2000;15:329\u201333.","journal-title":"Int Clin Psychopharmacol"},{"key":"2782_CR44","doi-asserted-by":"publisher","first-page":"176","DOI":"10.2174\/1574886313666180605095130","volume":"13","author":"J Read","year":"2018","unstructured":"Read J, Williams J. Adverse effects of antidepressants reported by a large international cohort: emotional blunting, suicidality, and withdrawal effects. Curr Drug Saf. 2018;13:176\u201386.","journal-title":"Curr Drug Saf"},{"key":"2782_CR45","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3233\/JRS-180018","volume":"29","author":"T Stockmann","year":"2018","unstructured":"Stockmann T, Odegbaro D, Timimi S, Moncrieff J. SSRI and SNRI withdrawal symptoms reported on an internet forum. Int J Risk Saf Med. 2018;29:175\u201380.","journal-title":"Int J Risk Saf Med"},{"key":"2782_CR46","doi-asserted-by":"publisher","first-page":"204512532098057","DOI":"10.1177\/2045125320980573","volume":"10","author":"MP Hengartner","year":"2020","unstructured":"Hengartner MP, Schulthess L, Sorensen A, Framer A. Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum. Ther Adv Psychopharmacol. 2020;10:2045125320980573.","journal-title":"Ther Adv Psychopharmacol"},{"key":"2782_CR47","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.4088\/JCP.v66n1015","volume":"66","author":"A Sir","year":"2005","unstructured":"Sir A, D\u2019Souza RF, Uguz S, George T, Vahip S, Hopwood M, et al. Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. J Clin Psychiatry. 2005;66:1312\u201320.","journal-title":"J Clin Psychiatry"},{"key":"2782_CR48","first-page":"18m02311","volume":"20","author":"A Papp","year":"2018","unstructured":"Papp A, Onton JA. Brain zaps: an underappreciated symptom of antidepressant discontinuation. Prim Care Companion CNS Disord. 2018;20:18m02311.","journal-title":"Prim Care Companion CNS Disord"},{"key":"2782_CR49","unstructured":"NICE & guideline. (NICE: Recommendations, https:\/\/www.nice.org.uk\/guidance\/ng215, 2022)."},{"key":"2782_CR50","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s40263-022-00960-y","volume":"37","author":"MA Horowitz","year":"2023","unstructured":"Horowitz MA, Framer A, Hengartner MP, S\u00f8rensen A, Taylor D. Estimating risk of antidepressant withdrawal from a review of published data. CNS Drugs. 2023;37:143\u201357.","journal-title":"CNS Drugs"},{"key":"2782_CR51","unstructured":"Weller I, Ashby D, Chambers M, Chick J, Drummond C, Ebmeier K, et al. Report of the CSM Expert Working Group on the safety of selective serotonin reuptake inhibitors antidepressants. London: Medicines and Healthcare products Regulatory Agency, 2005."},{"key":"2782_CR52","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1159\/000370338","volume":"84","author":"GA Fava","year":"2015","unstructured":"Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom. 2015;84:72\u201381.","journal-title":"Psychother Psychosom"},{"key":"2782_CR53","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41380-021-01285-w","volume":"27","author":"A S\u00f8rensen","year":"2022","unstructured":"S\u00f8rensen A, Ruh\u00e9 HG, Munkholm K. The relationship between dose and serotonin transporter occupancy of antidepressants-a systematic review. Mol Psychiatry. 2022;27:192\u2013201.","journal-title":"Mol Psychiatry"},{"key":"2782_CR54","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/j.1368-5031.2006.00865.x","volume":"60","author":"HGM Westenberg","year":"2006","unstructured":"Westenberg HGM, Sandner C. Tolerability and safety of fluvoxamine and other antidepressants. Int J Clin Pract. 2006;60:482\u201391.","journal-title":"Int J Clin Pract"},{"key":"2782_CR55","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1007\/s40264-022-01246-4","volume":"45","author":"C Gastaldon","year":"2022","unstructured":"Gastaldon C, Schoretsanitis G, Arzenton E, Raschi E, Papola D, Ostuzzi G, et al. Withdrawal syndrome following discontinuation of 28 antidepressants: pharmacovigilance analysis of 31,688 reports from the WHO spontaneous reporting database. Drug Saf. 2022;45:1539\u201349.","journal-title":"Drug Saf"},{"key":"2782_CR56","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jad.2006.04.026","volume":"95","author":"D Taylor","year":"2006","unstructured":"Taylor D, Stewart S, Connolly A. Antidepressant withdrawal symptoms-telephone calls to a national medication helpline. J Affect Disord. 2006;95:129\u201333.","journal-title":"J Affect Disord"},{"key":"2782_CR57","first-page":"355","volume":"116","author":"J Henssler","year":"2019","unstructured":"Henssler J, Heinz A, Brandt L, Bschor T. Antidepressant withdrawal and rebound phenomena. Dtsch Arztebl Int. 2019;116:355\u201361.","journal-title":"Dtsch Arztebl Int"},{"key":"2782_CR58","doi-asserted-by":"publisher","first-page":"21831","DOI":"10.4088\/JCP.19com12794","volume":"80","author":"GA Fava","year":"2019","unstructured":"Fava GA, Cosci F. Understanding and managing withdrawal syndromes after discontinuation of antidepressant drugs. J Clin Psychiatry. 2019;80:21831.","journal-title":"J Clin Psychiatry"},{"key":"2782_CR59","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1159\/000371865","volume":"84","author":"G Chouinard","year":"2015","unstructured":"Chouinard G, Chouinard V-A. New classification of selective serotonin reuptake inhibitor withdrawal. Psychother Psychosom. 2015;84:63\u201371.","journal-title":"Psychother Psychosom"},{"key":"2782_CR60","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.mpmed.2016.09.007","volume":"44","author":"S Turton","year":"2016","unstructured":"Turton S, Lingford-Hughes A. Neurobiology and principles of addiction and tolerance. Medicine. 2016;44:693\u201396.","journal-title":"Medicine"},{"key":"2782_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(23)00230-4","volume":"10","author":"MA Horowitz","year":"2023","unstructured":"Horowitz MA, Taylor D. Addiction and physical dependence are not the same thing. Lancet Psychiatry. 2023;10:e23.","journal-title":"Lancet Psychiatry"},{"key":"2782_CR62","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0165-0327(98)00221-3","volume":"51","author":"SM Stahl","year":"1998","unstructured":"Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors: serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord. 1998;51:215\u201335.","journal-title":"J Affect Disord"},{"key":"2782_CR63","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1176\/appi.ajp.161.5.826","volume":"161","author":"JH Meyer","year":"2004","unstructured":"Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C] DASB positron emission tomography study. Am J Psychiatry. 2004;161:826\u201335.","journal-title":"Am J Psychiatry"},{"key":"2782_CR64","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1080\/17522439.2018.1469163","volume":"10","author":"PC Groot","year":"2018","unstructured":"Groot PC, van Os J. Antidepressant tapering strips to help people come off medication more safely. Psychosis. 2018;10:142\u201345.","journal-title":"Psychosis"},{"key":"2782_CR65","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/j.1875-9114.1996.tb03653.x","volume":"16","author":"GW Amsden","year":"1996","unstructured":"Amsden GW, Georgian F. Orthostatic hypotension induced by sertraline withdrawal. Pharmacother J Hum Pharmacol Drug Ther. 1996;16:684\u201386.","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"2782_CR66","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.euroneuro.2021.10.001","volume":"55","author":"MA Horowitz","year":"2022","unstructured":"Horowitz MA, Taylor D. How to reduce and stop psychiatric medication. Eur Neuropsychopharmacol. 2022;55:4\u20137.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2782_CR67","doi-asserted-by":"publisher","first-page":"204512532199127","DOI":"10.1177\/2045125321991274","volume":"11","author":"A Framer","year":"2021","unstructured":"Framer A. What I have learnt from helping thousands of people taper off antidepressants and other psychotropic medications. Ther Adv Psychopharmacol. 2021;11:2045125321991274.","journal-title":"Ther Adv Psychopharmacol"},{"key":"2782_CR68","unstructured":"RCPSYCH. (Royal College of Psychiatrists, www.rcpsych.ac.uk\/docs\/default-source\/improving-care\/better-mh-policy\/position-statements\/ps04_19---antidepressants-and-depression.pdf?sfvrsn=ddea9473_5, 2019)."}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02782-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02782-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02782-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:03:08Z","timestamp":1789113788000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02782-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,11]]},"references-count":68,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["2782"],"URL":"https:\/\/doi.org\/10.1038\/s41380-024-02782-4","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,11]]},"assertion":[{"value":"14 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MAH reports being a collaborating investigator on the RELEASE and RELEASE+ trials in Australia, funded by the MRFF and NHMRC, evaluating hyperbolic tapering of antidepressants against care as usual. MAH reports being a co-founder of and consultant to Outro Health Clinic, which aims to provide digital support for patients in the U.S. to help stop no longer needed antidepressant treatment. All the other authors declare no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All methods in this study were performed in accordance with the relevant guidelines and regulations. This systematic meta-review strictly followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and was preregistered on PROSPERO (CRD 42022304659). Because this study is a meta-analysis and systematic review, the informed consent obtained from all participants does not apply to this study.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}